Skip to main content

Table 1 Reimbursement status and recommendations issued for analysed drugs in 2017

From: Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe

Medicine name Active substance Approval type Recommendation/reimbursement In analysed countries
Bulgaria Croatia Czechia Estonia Hungary Latvia Lithuania Poland Romania Slovakia
Adcetris Brentuximab vedotin Conditional approval / / ./✗ / / ./✗ ./✗ / ./✗ ./✗
Arzerra Ofatumumab Unconditional / / ./✗ ./✗ ✗/✗ ./✗ ./✗ ✗/✗ / /
Atriance Nelarabine Exceptional circumstances / ./✗ /✗ ./✗ / ✗/✗ ./✗ / / ./✗
Blincyto Blinatumomab Conditional approval ./✗ ./✗ ./✗ ./✗ ✗/✗ ./✗ ./✗ /✗ ./✗ ./✗
Bosulif Bosutinib Conditional approval / ./ ./✗ / / / ./✗ ✗/ / ./✗
Ceplene Histamine dihydrochloride Exceptional circumstances ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗
Cometriq Cabozantinib Conditional approval ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ✗/✗ ./✗ ./✗
Dacogen Decitabine Unconditional ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ / ./✗
Darzalex Daratumumab Conditional approval ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ✗/✗ ./✗ ✗/✗
Farydak Panobinostat lactate anhydrous Unconditional ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ✗/✗ ./✗ ./✗
Gazyvaro Obinutuzumab Unconditional ./✗ / / ./✗ / / / / ./✗ /
Gliolan 5-aminolevulinic acid hydrochloride Unconditional ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗
Iclusig Ponatinib Unconditional ./✗ ./✗ ./✗ ./✗ ✗/✗ ./✗ ./✗ /✗ ./✗ /
Imbruvica Ibrutinib Unconditional / ./✗ ./✗ / / ./✗ / ✗/ ./✗ /
Imnovida Pomalidomide Unconditional ./✗ ./✗ / ./✗ ./✗ ./✗ ./✗ ✗/✗ ./✗ ✗/✗
Kyprolis Carfilzomib Unconditional ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗
Lartruvo Olaratumab Conditional approval ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗
Lenvima Lenvatinib mesylate Unconditional ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗
Lynparza Olaparib Unconditional / ./ ./✗ / ./✗ ./✗ / ✗/ ./✗ ./✗
Mepact Mifamurtide Unconditional ./✗ ./✗ / / ✗/✗ ./✗ ./✗ ✗/✗ ./✗ ✗/✗
Nexavar Sorafenib Unconditional / / / / / ./✗ / ✗/ ./✗ /
Ninlaro Ixazomib citrate Conditional approval ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗
Onivyde Irinotecan hydrochloride trihydrate Unconditional ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗
Revlimid Lenalidomide Unconditional ./✗ ./ / / / ✗/✗ / / ./✗ /
Sprycel Dasatinib Unconditional / / / / / / / / / /
Tasigna Nilotinib Unconditional / /✗ / / / / / / / /
Tepadina Thiotepa Unconditional ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./ ./✗ ./✗
Thalidomide Celgeneb Thalidomide Unconditional ./✗ ./✗ ./✗ / / ./✗ / ✗/✗ ./ ./✗
Torisel Temsirolimus Unconditional / /✗ / ./✗ / ✗/✗ ./✗ ✗/ ./✗ /
Unituxin Dinutuximab Unconditional ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗
Venclyxto Venetoclax Conditional approval ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗
Vidaza Azacitidine Unconditional / /✗ / / ./✗ ./✗ / / ./✗ /
Votubia Everolimus Unconditional / /✗ ./✗ / ./✗ ./✗ / / / ./✗
Xaluprinec 6-mercaptopurine monohydrate Unconditional / ./✗ / / / ./✗ ./✗ ./✗ ./✗ ./✗
Yondelis Trabectedin Unconditional ./✗ /✗ ./✗ ./✗ ✗/✗ ✗/✗ ./✗ / / ./✗
Zalmoxis Allogeneic T cells genetically modified Conditional approval ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗ ./✗
  1. Scheme: recommendation/reimbursement
  2. —positive; ✗—negative;.—not issued
  3. aPreviously pomalidomide celgene
  4. bPreviously thalidomide pharmion
  5. cMercaptopurine nova laboratories